 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...176177178179180181182183184185186...235236» |
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment open: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Nov 27, 2018
P2, N=140, Recruiting, Sponsor: UNICANCER
Active, not recruiting --> Recruiting
- | dilpacimab (ABT-165) / AbbVie
Trial primary completion date, Metastases: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (clinicaltrials.gov) - Nov 26, 2018
P2, N=100, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Recruiting Trial primary completion date: Feb 2020 --> Aug 2020
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment open: CR-SEQUENCE: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (clinicaltrials.gov) - Nov 26, 2018
P3, N=370, Recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Feb 2020 --> Aug 2020 Not yet recruiting --> Recruiting
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Combination therapy: Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 23, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Mar 2023 --> Mar 2022
- | Vectibix (panitumumab) / Amgen
New P2 trial: BEYOND: Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (clinicaltrials.gov) - Nov 23, 2018
P2, N=85, Recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
- | Modufolin (arfolitixorin) / Isofol Medical, Solasia
New P3 trial, Combination therapy, Metastases: AGENT: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 22, 2018
P3, N=440, Not yet recruiting, Sponsor: Isofol Medical AB
- | New trial, Metastases: CANWATCH: Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis (clinicaltrials.gov) - Nov 21, 2018
P=N/A, N=650, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | New P2 trial, Circulating tumor DNA: IMPROVE-IT: IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer (clinicaltrials.gov) - Nov 21, 2018
P2, N=64, Recruiting, Sponsor: Karen-Lise Garm Spindler
- | dilpacimab (ABT-165) / AbbVie
Enrollment open, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Nov 21, 2018
P1, N=95, Recruiting, Sponsor: AbbVie
Trial completion date: Mar 2023 --> Mar 2022 Active, not recruiting --> Recruiting
- | dilpacimab (ABT-165) / AbbVie
Trial completion date, Metastases: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (clinicaltrials.gov) - Nov 20, 2018
P2, N=100, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Recruiting Trial completion date: Feb 2020 --> Aug 2020
- | Rituxan (rituximab) / Roche
Enrollment open: LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) - Nov 16, 2018
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Feb 2020 --> Aug 2020 Not yet recruiting --> Recruiting
- | epacadostat (INCB024360) / Incyte
Trial completion date, Trial initiation date, Trial primary completion date: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Nov 15, 2018
P1/2, N=57, Not yet recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial completion date: May 2022 --> Aug 2022 | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: May 2022 --> Aug 2022
- | Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Nov 14, 2018
P3, N=823, Active, not recruiting, Sponsor: Takeda
Trial completion date: May 2022 --> Aug 2022 | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: May 2022 --> Aug 2022 Trial completion date: May 2020 --> Mar 2020 | Trial primary completion date: May 2020 --> Mar 2020
- | Farydak (panobinostat) / Secura Bio
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 14, 2018
P1, N=19, Terminated, Sponsor: St. Jude Children's Research Hospital
Trial completion date: May 2020 --> Mar 2020 | Trial primary completion date: May 2020 --> Mar 2020 N=36 --> 19 | Trial completion date: Aug 2020 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Apr 2018; Slow accrual
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open, Metastases: Avenger 500: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Nov 14, 2018
P3, N=500, Recruiting, Sponsor: Rafael Pharmaceuticals Inc.
N=36 --> 19 | Trial completion date: Aug 2020 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Apr 2018; Slow accrual Not yet recruiting --> Recruiting
- | monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Phase classification, Enrollment change, Trial primary completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Nov 13, 2018
P1/2, N=501, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Phase classification: P1 --> P1/2 | N=262 --> 501 | Trial primary completion date: Feb 2020 --> Oct 2021
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, IO biomarker: AIO-STO-0417: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Nov 13, 2018
P2, N=118, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Phase classification: P1 --> P1/2 | N=262 --> 501 | Trial primary completion date: Feb 2020 --> Oct 2021 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion: ITACa: Sequential Treatment Strategy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 9, 2018
P3, N=350, Completed, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion date, Trial initiation date, Trial primary completion date: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - Nov 9, 2018
P3, N=140, Not yet recruiting, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Trial completion date: Mar 2025 --> Sep 2025 | Initiation date: Sep 2018 --> Mar 2019 | Trial primary completion date: Mar 2023 --> Sep 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 (clinicaltrials.gov) - Nov 9, 2018
P2, N=90, Recruiting, Sponsor: Shanghai Changzheng Hospital
Trial completion date: Mar 2025 --> Sep 2025 | Initiation date: Sep 2018 --> Mar 2019 | Trial primary completion date: Mar 2023 --> Sep 2023 Trial completion date: Nov 2020 --> Nov 2021 | Initiation date: Nov 2017 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Nov 2018
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (clinicaltrials.gov) - Nov 9, 2018
P2, N=196, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Trial completion date: Nov 2020 --> Nov 2021 | Initiation date: Nov 2017 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Nov 2018 Not yet recruiting --> Recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
New P2 trial, Metastases: NCI-2018-02122: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin (clinicaltrials.gov) - Nov 9, 2018
P2, N=37, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- | Odomzo (sonidegib) / Sun Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 8, 2018
P1b, N=39, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Aug 2018 --> Mar 2019
- | conatumumab (AMG 655) / Amgen
Trial completion date, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Nov 6, 2018
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial completion date: Aug 2018 --> Mar 2019 | Trial primary completion date: Aug 2018 --> Mar 2019 Trial completion date: Jan 2019 --> Nov 2019 | Trial primary completion date: Jan 2019 --> Sep 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) - Nov 6, 2018
P2, N=138, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jan 2019 --> Nov 2019 | Trial primary completion date: Jan 2019 --> Sep 2019 Trial completion date: Oct 2018 --> Oct 2021 | Trial primary completion date: Oct 2018 --> Oct 2020
- | leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Nov 6, 2018
P1, N=18, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Oct 2018 --> Oct 2021 | Trial primary completion date: Oct 2018 --> Oct 2020 Trial completion date: Oct 2018 --> Jun 2019 | Trial primary completion date: Oct 2018 --> Jun 2019
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Nov 6, 2018
P3, N=1649, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Oct 2018 --> Jun 2019 | Trial primary completion date: Oct 2018 --> Jun 2019 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Mar 2020 --> Mar 2021
- | epacadostat (INCB024360) / Incyte
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) (clinicaltrials.gov) - Nov 6, 2018
P1/2, N=70, Active, not recruiting, Sponsor: Incyte Corporation
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Mar 2020 --> Mar 2021 Recruiting --> Active, not recruiting | N=421 --> 70 | Trial completion date: Oct 2022 --> Jan 2020 | Trial primary completion date: Apr 2021 --> Oct 2019
- | Enrollment open, Trial initiation date: Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy (clinicaltrials.gov) - Nov 6, 2018
P3, N=764, Recruiting, Sponsor: LI XIN-XIANG
Recruiting --> Active, not recruiting | N=421 --> 70 | Trial completion date: Oct 2022 --> Jan 2020 | Trial primary completion date: Apr 2021 --> Oct 2019 Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Nov 2018
- | Enrollment closed: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Nov 6, 2018
P1/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Nov 2018 Recruiting --> Active, not recruiting
- || AZD0156 / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Nov 5, 2018
P1, N=225, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial completion date: Oct 2020 --> Aug 2019 | Trial primary completion date: Oct 2020 --> Aug 2019
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial suspension: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Nov 5, 2018
P2, N=116, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2020 --> Aug 2019 | Trial primary completion date: Oct 2020 --> Aug 2019 Recruiting --> Suspended
- | pegilodecakin (LY3500518) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Sequoia: Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 2, 2018
P3, N=566, Recruiting, Sponsor: ARMO BioSciences
Recruiting --> Suspended Trial completion date: Jan 2020 --> Mar 2020 | Trial primary completion date: Jan 2019 --> Mar 2020
- ||| 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 30, 2018
P2, N=111, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jan 2020 --> Mar 2020 | Trial primary completion date: Jan 2019 --> Mar 2020 Active, not recruiting --> Completed | Trial completion date: Oct 2019 --> Oct 2018 | Trial primary completion date: Oct 2019 --> Oct 2018
- | New P2 trial: Phase ? Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE (clinicaltrials.gov) - Oct 29, 2018
P2, N=90, Recruiting, Sponsor: Sun Yat-sen University
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New P2 trial, Metastases: AtezoTRIBE: FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Oct 25, 2018
P2, N=201, Not yet recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- | Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Combination therapy, Metastases: CHARTA: Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 25, 2018
P2, N=250, Completed, Sponsor: Martin-Luther-Universit
Active, not recruiting --> Completed | Trial completion date: Oct 2019 --> Oct 2018 | Trial primary completion date: Oct 2019 --> Oct 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Aug 2018
- | 5-fluorouracil / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Oct 25, 2018
P1, N=14, Active, not recruiting, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Aug 2018 Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2017 --> May 2018
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Oct 25, 2018
P2, N=43, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2017 --> May 2018 Recruiting --> Active, not recruiting
- ||||| abituzumab (EMD 525797) / EMD Serono, SFJ Pharma
New P2 trial, Combination therapy, Metastases: AMELION: Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Oct 24, 2018
P2, N=230, Not yet recruiting, Sponsor: SFJ Pharmaceuticals X, LTD.
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial completion date, Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Oct 23, 2018
P=N/A, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Aug 2018 --> Aug 2019
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date, HEOR: SILQ: ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (clinicaltrials.gov) - Oct 22, 2018
P=N/A, N=300, Recruiting, Sponsor: Amgen
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion date, Metastases: Avenger 500: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Oct 22, 2018
P3, N=500, Not yet recruiting, Sponsor: Rafael Pharmaceuticals Inc.
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Mar 2023 --> Mar 2022
- | New P2 trial, Metastases: Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine (clinicaltrials.gov) - Oct 21, 2018
P2, N=42, Not yet recruiting, Sponsor: HonorHealth Research Institute
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., palonosetron intravenous / Generic mfg.
Clinical, Journal: A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. (Pubmed Central) - Oct 21, 2018
To our knowledge, these two drugs have never been described in the literature as a cause of DDPA. We suggest that OIIS in addition to oxaliplatin-induced thrombocytopenia may be associated with the development of DDPAs to other drugs causing clinically significant thrombocytopenia which is important to recognize and manage with discontinuation of provoking agents.
- || veliparib (ABT-888) / AbbVie
Trial completion date, Trial primary completion date, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 19, 2018
P1/2, N=79, Recruiting, Sponsor: Georgetown University
We suggest that OIIS in addition to oxaliplatin-induced thrombocytopenia may be associated with the development of DDPAs to other drugs causing clinically significant thrombocytopenia which is important to recognize and manage with discontinuation of provoking agents. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Enrollment closed: Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 19, 2018
P2, N=100, Active, not recruiting, Sponsor: University of California, San Diego
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial: T2317: Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy (clinicaltrials.gov) - Oct 19, 2018
P2, N=52, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
- | Avastin (bevacizumab) / Roche
New P2 trial: The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Oct 17, 2018
P2, N=40, Not yet recruiting, Sponsor: National Cheng-Kung University Hospital
- | Enrollment open, Metastases: Short-course Radiotherapy (5 (clinicaltrials.gov) - Oct 17, 2018
P1, N=9, Recruiting, Sponsor: Fujian Medical University Union Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting